17-hydroxyprogesterone

Keywords: 17 OH Progesterone, 17-OHP, Hydroxy progesterone

Description:

Steroids

Specimen:

5 mL blood in SST/serum tube. Some laboratories may offer an assay on dried blood spot on filter paper.

Method:

Immunoassay, LC-MS/MS

Protocol:

Collect pre dose specimen (trough) if patient on therapy for CAH.

Reference Interval:

Depends on age and phase of cycle (higher in luteal phase) - consult pathologist.

Application:

Diagnosis, monitoring and management of congenital adrenal hyperplasia (CAH).

Increased in some rare adrenal tumours.

Included in neonatal screening programs.

In mildly affected patients, measurement after adrenal stimulation with Synacthen® may be required to confirm the diagnosis.

Interpretation:

An increased level indicates 21-hydroxylase deficiency.

In patients with CAH due to 21-hydroxylase deficiency, monitoring treatment may require levels at various times of the day. Levels should not be markedly elevated and should not be suppressed immediately prior to the next dose of glucocorticoid.

SNOMED-CT ID:
41668001
LOINC:14569-8
Reference:

Auer MK. Congenital adrenal hyperplasia. Lancet 2023; 401: 227-44.

Honour JW. 17-Hydroxyprogesterone in children, adolescents and adults. Ann Clin Biochem 2014; 51: 424-40.

Resource:

Pathology Tests Explained - 17-hydroxyprogesterone

Medicare:

MBS Rebatable see Medical Benefits Scheme Category 6 Pathology Services

Last Reviewed:02 Jan 2024

Go Back

Page last updated:

Royal College of Pathologists of Australasia © 2024 . Apart from any use that is permitted under the Copyright Act 1968 (Cth), and any permissions explicitly granted by Royal College of Pathologists of Australasia, all other rights are reserved.

06-Feb-2024
Top